Sugi Predict

Sugi Predict / Compounds / SCHEMBL931389

SCHEMBL931389

SCHEMBL931389

OCCc1ccc(N2CCOCC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC13A5 Q86YT5 1/20 0.52
▸ MAPT P10636 6/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ KDM4E B2RXH2 4/20 0.49
▸ ALOX15 P16050 3/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ GSK3B P49841 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ RAB9A P51151 4/20 0.48
▸ NPC1 O15118 3/20 0.48
▸ HTT P42858 3/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ PIK3CA P42336 1/20 0.48
▸ MTOR P42345 1/20 0.48
▸ PIK3CG P48736 1/20 0.48
▸ GAA P10253 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10895294 0.92 SLC13A5 (0.47) SLC13A5MAPTALDH1A1KDM4EALOX15
SCHEMBL22558673 0.89 SLC13A5 (0.50) SLC13A5MAPTALDH1A1KDM4EALOX15
SCHEMBL1532698 0.87 SLC13A5 (0.49) SLC13A5MAPTALDH1A1KDM4EALOX15
SCHEMBL4809382 0.84 CHKA (0.51) MAPTALDH1A1KDM4EALOX15HSD17B10
SCHEMBL1716021 0.84 CHKA (0.56) SLC13A5MAPTALDH1A1KDM4EALOX15
SCHEMBL12676672 0.82 CHKA (0.53) MAPTALDH1A1KDM4EALOX15HSD17B10
SCHEMBL25291736 0.81 LMNA (0.64) SLC13A5MAPTALDH1A1RAB9ANPC1
SCHEMBL1681747 0.81 GSK3B (0.53) SLC13A5MAPTALDH1A1KDM4EALOX15
SCHEMBL7954719 0.81 SLC13A5 (0.49) SLC13A5MAPTALDH1A1KDM4EALOX15
SCHEMBL13061369 0.81 MAPT (0.52) SLC13A5MAPTALDH1A1KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104710385-B PDE10 inhibitor and compositions related and method 奥默罗斯公司 2018-11-09 — — CN disclosed
CN-107445919-A PDE10 inhibitor and compositions related and method 奥默罗斯公司 2017-12-08 — — CN disclosed
EP-2448939-B1 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THE PREPARATION AND PHARMACEUTICAL USE THEREOF SANOFI SA (FR) 2017-03-01 — — EP disclosed
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 — — EP disclosed
US-8828997-B2 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof SANOFI (FR) 2014-09-09 — — US disclosed
US-20120142679-A1 NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF SANOFI (FR) 2012-06-07 — — US disclosed
EP-2448939-A1 NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF SANOFI (FR) 2012-05-09 — — EP disclosed
WO-2011001112-A1 NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF SANOFI-AVENTIS (FR) 2011-01-06 — — WO disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 — — US disclosed
US-7320973-B2 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same AJINOMOTO CO., INC. (JP) 2008-01-22 — — US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 — — US disclosed
EP-1606268-A1 HETEROCYCLIC KINASE INHIBITORS Abbott Laboratories (US) 2005-12-21 — — EP disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 — — US disclosed
WO-2004076424-A1 HETEROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-10 — — WO disclosed
US-20040110742-A1 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same AJINOMOTO CO., INC. (JP) 2004-06-10 — — US disclosed
EP-1403258-A1 DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE Ajinomoto Co., Inc. (JP) 2004-03-31 — — EP disclosed
US-5006556-A Dichloroaniline derivatives for the therapy or prophylaxysis of a disease associated with reversible airway obstruction GLAXO GROUP LIMITED (GB) 1991-04-09 — — US disclosed
US-4943591-A TREATMENT OF ASTHMA AND BRONCHITIS GLAXO GROUP LIMITED (GB) 1990-07-24 — — US disclosed
EP-0181709-B1 DICHLOROANILINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1990-05-09 — — EP disclosed
CN-86102680-A The preparation method of process for dichloroaniline derivatives and purposes — 1987-10-28 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 SLC13A5 4415/4885MAPT 4057/4885ALDH1A1 2391/4885
US-20040110742-A1 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same CYP3A4, PPARD, CYP4B1 SLC13A5 2341/4885MAPT 1722/4885ALDH1A1 276/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 SLC13A5 4445/4885MAPT 3753/4885ALDH1A1 3257/4885
US-20120142679-A1 NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF LPXN, LBR, HCLS1 SLC13A5 357/4885MAPT 2593/4885ALDH1A1 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.